<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00561951</url>
  </required_header>
  <id_info>
    <org_study_id>A0221005</org_study_id>
    <nct_id>NCT00561951</nct_id>
  </id_info>
  <brief_title>Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo For Overactive Bladder.</brief_title>
  <official_title>A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo In Patients With Overactive Bladder.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of fesoterodine in comparison to placebo for overactive
      bladder.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 12.</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Number of urgency urinary incontinence episodes was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
Urgency urinary incontinence is the complaint of involuntary leakage accompanied by or immediately preceded by urgency. Urgency is the complaint of a sudden compelling desire to pass urine which is difficult to defer.
Change: mean at Week 12 minus mean at Baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Weeks 2, 4, 8, and 12.</measure>
    <time_frame>Baseline to Weeks 2, 4, 8, and 12</time_frame>
    <description>Number of urgency urinary incontinence (UUI) episodes was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
Urgency urinary incontinence is the complaint of involuntary leakage accompanied by or immediately preceded by urgency. Urgency is the complaint of a sudden compelling desire to pass urine which is difficult to defer.
Change: mean at each visit minus mean at Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Number of Micturitions Per 24 Hours at Week 12.</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Number of micturitions was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
Change: mean at Week 12 minus mean at Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Number of Micturitions Per 24 Hours at Weeks 2, 4, 8, and 12.</measure>
    <time_frame>Baseline to Weeks 2, 4, 8, and 12</time_frame>
    <description>Number of micturitions was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
Change: mean at each visit minus mean at Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Number of Urgency Episodes Per 24 Hours at Week 12.</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Number of urgency episodes was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
Urgency is the complaint of a sudden compelling desire to pass urine which is difficult to defer.
Change: mean at Week 12 minus mean at Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Number of Urgency Episodes Per 24 Hours at Weeks 2, 4, 8, and 12.</measure>
    <time_frame>Baseline to Weeks 2, 4, 8, and 12</time_frame>
    <description>Number of urgency episodes was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
Urgency is the complaint of a sudden compelling desire to pass urine which is difficult to defer.
Change: mean at each visit minus mean at Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Number of Incontinence Episodes Per 24 Hours at Week 12.</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Number of incontinence episodes was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
Incontinence is the complaint of any involuntary leakage of urine.
Change: mean at Week 12 minus mean at Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Number of Incontinence Episodes Per 24 Hours at Weeks 2, 4, 8, and 12.</measure>
    <time_frame>Baseline to Weeks 2, 4, 8, and 12</time_frame>
    <description>Number of incontinence episodes was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
Incontinence is the complaint of any involuntary leakage of urine.
Change: mean at each visit minus mean at Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Number of Night-Time Micturitions Per 24 Hours at Week 12.</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Number of Night-Time Micturitions was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
Change: mean at Week 12 minus mean at Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Number of Night-Time Micturitions Per 24 Hours at Weeks 2, 4, 8, and 12.</measure>
    <time_frame>Baseline to Weeks 2, 4, 8, and 12</time_frame>
    <description>Number of Night-Time Micturitions was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
Change: mean at each visit minus mean at Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Voided Volume Per Micturition at Week 12.</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Voided volume per micturition was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
Voided volume was recorded during any 1 day of 3-day diary period through the first micturition of the next day.
Change: mean at Week 12 minus mean at Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Voided Volume Per Micturition at Weeks 2, 4, 8, and 12.</measure>
    <time_frame>Baseline to Weeks 2, 4, 8, and 12</time_frame>
    <description>Voided volume per micturition was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
Change: mean at each visit minus mean at Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Each Domain Scores of King's Health Questionnaire (KHQ).</measure>
    <time_frame>Baseline to Week12</time_frame>
    <description>King's Health Questionnaire(KHQ) is used to assess the impact of bladder problems on quality of life. The each domain score was calculated valued and ranged from 0 to 100, where 0=best outcome/response and 100=worst outcome/response.
Change: mean at Week 12 minus mean at Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Each Domain Scores of Overactive Bladder Questionnaire (OAB-q) at Week 12.</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>The overactive bladder questionnaire (OAB-q) is used to assess the extent of participants who had been bothered by selected bladder symptoms and to assess the effect on their health-related quality of life (HRQL).
The each domain score ranges from 0 to 100 is a calculated value, where 0=minimal symptom severity and 100=greatest symptom severity for Symptom Bother Score, and where 0=worst HRQL outcome/response and 100=best HRQL outcome/response for HRQL domains including total score of HROL domain.
Change: mean at Week 12 minus mean at Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline for Patient Perception of Bladder Condition (PPBC) at Week 12.</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Patient Perception of Bladder Condition (PPBC) score is rated on a 6-point scale as follows:
No problems at all
Some very minor problems
Some minor problems
Some moderate problems
Severe problems
Many severe problems
Change: mean at Week 12 minus mean at Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Patients With &quot;Severe Problems, Score 5&quot; or &quot;Many Severe Problems, Score 6&quot; in Patient Perception of Bladder Condition (PPBC) at Week 12.</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Patient Perception of Bladder Condition (PPBC) score is rated on a 6-point scale as follows:
No problems at all
Some very minor problems
Some minor problems
Some moderate problems
Severe problems
Many severe problems</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">951</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>Fesoterodine fumarate 4 mg (Double-Blind)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Double-Blind)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fesoterodine fumarate 8 mg (Double-Blind)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fesoterodine fumarate</intervention_name>
    <description>8mg tablets OD for 12 weeks</description>
    <arm_group_label>Fesoterodine fumarate 8 mg (Double-Blind)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Corresponding placebo tablets OD for 12 weeks</description>
    <arm_group_label>Placebo (Double-Blind)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fesoterodine fumarate</intervention_name>
    <description>4mg tablets OD for 12 weeks</description>
    <arm_group_label>Fesoterodine fumarate 4 mg (Double-Blind)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult OAB patients who present with OAB symptoms, including micturitions &gt;= 8 per day
             and urgency urinary incontinence &gt;= 1 per day.

        Exclusion Criteria:

          -  Patient has known hypersensitivity to the active substance (fesoterodine fumarate) or
             to peanut or soya or any of the excipients.

          -  Patient has a known neurological disease influencing bladder function.

          -  Patient has a complication of lower urinary tract pathology potentially responsible
             for urgency or incontinence, clinically relevant bladder outlet obstruction or pelvic
             organ prolapse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kowloon</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chuo-ku, Chiba-shi</city>
        <state>Chiba-ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Eiheiji-cyo,yoshida-gun,</city>
        <state>Fukui-ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fukuoka-Shi</city>
        <state>Fukuoka-Ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Koga-shi</city>
        <state>Fukuoka-ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Minami-ku, Fukuoka-shi</city>
        <state>Fukuoka-ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nishi-ku</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sawara-ku</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Amagasaki-shi</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Suma-ku, Kobe-shi</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Higashinada</city>
        <state>Hyougo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nada-ku, Kobe-shi</city>
        <state>Hyougo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Takaraduka-city</city>
        <state>Hyougo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Aira-gun, Aira-chou,</city>
        <state>Kagosima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kawasakishi</city>
        <state>Kanagawaken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Isogo-ku, Yokohama-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sagamihara-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tama-ku, Kawasaki-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kouchi-shi</city>
        <state>Kouchi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tamana-shi</city>
        <state>Kumamoto-ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Matumoto-Shi</city>
        <state>Nagano-Ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Matsumoto-shi</city>
        <state>Nagano</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hunaki-cho, Ibaraki-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kita-ku, Osaka-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kosobe-cho, Takatsuki-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Minami-ku, Sakai-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nishinari-ku</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Suita-shi,</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Suita-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Toyonaka-city</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Yodogawa-Ku</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Saitama-shi</city>
        <state>Saitama-ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Satte-shi</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Wakou-shi</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gotenbashi</city>
        <state>Shizuokaken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Susono</city>
        <state>Shizuokaken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chofu-shi</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fucyushi</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Koto-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nakano-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nishitokyo-shi</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Setagaya-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Setgaya-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Shibuya-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Suginami-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sumida-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chuou-shi</city>
        <state>Yamanashi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cheonan-si</city>
        <state>Chungcheongnam-do</state>
        <zip>330-715</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pusan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>100-380</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chiayi Country</city>
        <zip>613</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hualien</city>
        <zip>970</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Koahsiung</city>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Taichung</city>
        <zip>402</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0221005&amp;StudyName=Dose-Finding%20Study%20To%20Evaluate%20The%20Efficacy%2C%20Tolerability%20And%20Safety%20Of%20Fesoterodine%20In%20Comparison%20To%20Placebo%20For%20Overactive%20Bladder.</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2007</study_first_submitted>
  <study_first_submitted_qc>November 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2007</study_first_posted>
  <results_first_submitted>January 11, 2010</results_first_submitted>
  <results_first_submitted_qc>August 18, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 9, 2010</results_first_posted>
  <last_update_submitted>July 11, 2011</last_update_submitted>
  <last_update_submitted_qc>July 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2011</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer Inc</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fesoterodine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Eligible subjects who underwent screening were enrolled into the run-in period at visit 1 and received single-blind placebo for 2 weeks. At Visit 2, Only subjects with overactive bladder who met the criteria were randomized to one of three treatment arms (fesoterodine 4 mg, fesoterodine 8 mg or placebo) in a 1:1:1 ratio.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Subjects were treated with placebo once daily for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Fesoterodine 4 mg</title>
          <description>Subjects were treated with Fesoterodine 4 mg/day for 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Fesoterodine 8 mg</title>
          <description>Subjects were treated with Fesoterodine 8 mg/day for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="318"/>
                <participants group_id="P2" count="320"/>
                <participants group_id="P3" count="313"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="285"/>
                <participants group_id="P2" count="286"/>
                <participants group_id="P3" count="281"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="32"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Meet Withdrawal Criterion</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event Occured Before Treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Subjects were treated with placebo once daily for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Fesoterodine 4 mg</title>
          <description>Subjects were treated with Fesoterodine 4 mg/day for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Fesoterodine 8 mg</title>
          <description>Subjects were treated with Fesoterodine 8 mg/day for 12 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="318"/>
            <count group_id="B2" value="320"/>
            <count group_id="B3" value="313"/>
            <count group_id="B4" value="951"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="227"/>
                    <measurement group_id="B2" value="217"/>
                    <measurement group_id="B3" value="196"/>
                    <measurement group_id="B4" value="640"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="117"/>
                    <measurement group_id="B4" value="311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.7" spread="13.5"/>
                    <measurement group_id="B2" value="57.2" spread="14.2"/>
                    <measurement group_id="B3" value="58.8" spread="13.4"/>
                    <measurement group_id="B4" value="57.6" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="251"/>
                    <measurement group_id="B2" value="251"/>
                    <measurement group_id="B3" value="255"/>
                    <measurement group_id="B4" value="757"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 12.</title>
        <description>Number of urgency urinary incontinence episodes was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
Urgency urinary incontinence is the complaint of involuntary leakage accompanied by or immediately preceded by urgency. Urgency is the complaint of a sudden compelling desire to pass urine which is difficult to defer.
Change: mean at Week 12 minus mean at Baseline.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subjects were treated with placebo once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 4 mg</title>
            <description>Subjects were treated with Fesoterodine 4 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg</title>
            <description>Subjects were treated with Fesoterodine 8 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 12.</title>
          <description>Number of urgency urinary incontinence episodes was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
Urgency urinary incontinence is the complaint of involuntary leakage accompanied by or immediately preceded by urgency. Urgency is the complaint of a sudden compelling desire to pass urine which is difficult to defer.
Change: mean at Week 12 minus mean at Baseline.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>UUI Episodes</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="314"/>
                <count group_id="O3" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.01" lower_limit="-1.31" upper_limit="-0.71"/>
                    <measurement group_id="O2" value="-1.35" lower_limit="-1.65" upper_limit="-1.05"/>
                    <measurement group_id="O3" value="-1.40" lower_limit="-1.70" upper_limit="-1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The significance level was 0.05 (2-sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>The closed testing procedure was used in order to control the probability of a type 1 error.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance model with the treatment group, region as fixed effects and baseline values as a covariate was used.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.56</ci_lower_limit>
            <ci_upper_limit>-0.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The significance level was 0.05 (2-sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The closed testing procedure was used in order to control the probability of a type 1 error.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance model with the treatment group, region as fixed effects and baseline values as a covariate was used.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.60</ci_lower_limit>
            <ci_upper_limit>-0.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Weeks 2, 4, 8, and 12.</title>
        <description>Number of urgency urinary incontinence (UUI) episodes was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
Urgency urinary incontinence is the complaint of involuntary leakage accompanied by or immediately preceded by urgency. Urgency is the complaint of a sudden compelling desire to pass urine which is difficult to defer.
Change: mean at each visit minus mean at Baseline.</description>
        <time_frame>Baseline to Weeks 2, 4, 8, and 12</time_frame>
        <population>Full analysis set. No imputation was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subjects were treated with placebo once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 4 mg</title>
            <description>Subjects were treated with Fesoterodine 4 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg</title>
            <description>Subjects were treated with Fesoterodine 8 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Weeks 2, 4, 8, and 12.</title>
          <description>Number of urgency urinary incontinence (UUI) episodes was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
Urgency urinary incontinence is the complaint of involuntary leakage accompanied by or immediately preceded by urgency. Urgency is the complaint of a sudden compelling desire to pass urine which is difficult to defer.
Change: mean at each visit minus mean at Baseline.</description>
          <population>Full analysis set. No imputation was used for missing data.</population>
          <units>UUI Episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="314"/>
                <count group_id="O3" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=308, 314, 305)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.79" spread="1.465"/>
                    <measurement group_id="O2" value="-1.10" spread="1.681"/>
                    <measurement group_id="O3" value="-1.12" spread="1.736"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=301, 303, 296)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.15" spread="1.532"/>
                    <measurement group_id="O2" value="-1.48" spread="1.688"/>
                    <measurement group_id="O3" value="-1.49" spread="1.643"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=289, 289, 287)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.45" spread="1.518"/>
                    <measurement group_id="O2" value="-1.61" spread="1.680"/>
                    <measurement group_id="O3" value="-1.65" spread="1.690"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=284, 284, 281)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.49" spread="1.717"/>
                    <measurement group_id="O2" value="-1.76" spread="1.618"/>
                    <measurement group_id="O3" value="-1.87" spread="1.814"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Number of Micturitions Per 24 Hours at Week 12.</title>
        <description>Number of micturitions was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
Change: mean at Week 12 minus mean at Baseline.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subjects were treated with placebo once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 4 mg</title>
            <description>Subjects were treated with Fesoterodine 4 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg</title>
            <description>Subjects were treated with Fesoterodine 8 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Number of Micturitions Per 24 Hours at Week 12.</title>
          <description>Number of micturitions was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
Change: mean at Week 12 minus mean at Baseline.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>Micturitions</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="314"/>
                <count group_id="O3" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.59" lower_limit="-1.08" upper_limit="-0.10"/>
                    <measurement group_id="O2" value="-1.15" lower_limit="-1.64" upper_limit="-0.67"/>
                    <measurement group_id="O3" value="-1.25" lower_limit="-1.75" upper_limit="-0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The significance level was 0.05 (2-sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance model with the treatment group, region as fixed effects and baseline values as a covariate was used.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.91</ci_lower_limit>
            <ci_upper_limit>-0.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The significance level was 0.05 (2-sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance model with the treatment group, region as fixed effects and baseline values as a covariate was used.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.01</ci_lower_limit>
            <ci_upper_limit>-0.32</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Number of Micturitions Per 24 Hours at Weeks 2, 4, 8, and 12.</title>
        <description>Number of micturitions was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
Change: mean at each visit minus mean at Baseline.</description>
        <time_frame>Baseline to Weeks 2, 4, 8, and 12</time_frame>
        <population>Full analysis set. No imputation was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subjects were treated with placebo once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 4 mg</title>
            <description>Subjects were treated with Fesoterodine 4 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg</title>
            <description>Subjects were treated with Fesoterodine 8 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Number of Micturitions Per 24 Hours at Weeks 2, 4, 8, and 12.</title>
          <description>Number of micturitions was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
Change: mean at each visit minus mean at Baseline.</description>
          <population>Full analysis set. No imputation was used for missing data.</population>
          <units>Micturitions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="314"/>
                <count group_id="O3" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=308, 314, 305)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.47" spread="1.786"/>
                    <measurement group_id="O2" value="-0.94" spread="1.987"/>
                    <measurement group_id="O3" value="-1.06" spread="2.076"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=301, 303, 296)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.85" spread="1.960"/>
                    <measurement group_id="O2" value="-1.33" spread="2.146"/>
                    <measurement group_id="O3" value="-1.60" spread="2.246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=289, 289, 287)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.36" spread="2.215"/>
                    <measurement group_id="O2" value="-1.81" spread="2.277"/>
                    <measurement group_id="O3" value="-2.15" spread="2.402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=284, 284, 281)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.36" spread="2.415"/>
                    <measurement group_id="O2" value="-2.13" spread="2.214"/>
                    <measurement group_id="O3" value="-2.17" spread="2.515"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Number of Urgency Episodes Per 24 Hours at Week 12.</title>
        <description>Number of urgency episodes was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
Urgency is the complaint of a sudden compelling desire to pass urine which is difficult to defer.
Change: mean at Week 12 minus mean at Baseline.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subjects were treated with placebo once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 4 mg</title>
            <description>Subjects were treated with Fesoterodine 4 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg</title>
            <description>Subjects were treated with Fesoterodine 8 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Number of Urgency Episodes Per 24 Hours at Week 12.</title>
          <description>Number of urgency episodes was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
Urgency is the complaint of a sudden compelling desire to pass urine which is difficult to defer.
Change: mean at Week 12 minus mean at Baseline.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>Urgency Episodes</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="314"/>
                <count group_id="O3" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.00" lower_limit="-1.60" upper_limit="-0.40"/>
                    <measurement group_id="O2" value="-1.65" lower_limit="-2.25" upper_limit="-1.05"/>
                    <measurement group_id="O3" value="-1.66" lower_limit="-2.27" upper_limit="-1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The significance level was 0.05 (2-sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance model with the treatment group, region as fixed effects and baseline values as a covariate was used.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.07</ci_lower_limit>
            <ci_upper_limit>-0.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The significance level was 0.05 (2-sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance model with the treatment group, region as fixed effects and baseline values as a covariate was used.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.09</ci_lower_limit>
            <ci_upper_limit>-0.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Number of Urgency Episodes Per 24 Hours at Weeks 2, 4, 8, and 12.</title>
        <description>Number of urgency episodes was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
Urgency is the complaint of a sudden compelling desire to pass urine which is difficult to defer.
Change: mean at each visit minus mean at Baseline.</description>
        <time_frame>Baseline to Weeks 2, 4, 8, and 12</time_frame>
        <population>Full analysis set. No imputation was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subjects were treated with placebo once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 4 mg</title>
            <description>Subjects were treated with Fesoterodine 4 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg</title>
            <description>Subjects were treated with Fesoterodine 8 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Number of Urgency Episodes Per 24 Hours at Weeks 2, 4, 8, and 12.</title>
          <description>Number of urgency episodes was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
Urgency is the complaint of a sudden compelling desire to pass urine which is difficult to defer.
Change: mean at each visit minus mean at Baseline.</description>
          <population>Full analysis set. No imputation was used for missing data.</population>
          <units>Urgency Episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="314"/>
                <count group_id="O3" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=308, 314, 305)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.79" spread="2.640"/>
                    <measurement group_id="O2" value="-1.37" spread="2.722"/>
                    <measurement group_id="O3" value="-1.59" spread="2.816"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=301, 303, 296)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.60" spread="2.780"/>
                    <measurement group_id="O2" value="-2.16" spread="2.906"/>
                    <measurement group_id="O3" value="-2.16" spread="3.065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=289, 289, 287)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.34" spread="2.835"/>
                    <measurement group_id="O2" value="-2.50" spread="3.080"/>
                    <measurement group_id="O3" value="-2.71" spread="3.139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=284, 284, 281)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.37" spread="2.975"/>
                    <measurement group_id="O2" value="-2.89" spread="2.838"/>
                    <measurement group_id="O3" value="-3.05" spread="3.462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Number of Incontinence Episodes Per 24 Hours at Week 12.</title>
        <description>Number of incontinence episodes was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
Incontinence is the complaint of any involuntary leakage of urine.
Change: mean at Week 12 minus mean at Baseline.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>Full analysis set. Last observation carried forward</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subjects were treated with placebo once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 4 mg</title>
            <description>Subjects were treated with Fesoterodine 4 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg</title>
            <description>Subjects were treated with Fesoterodine 8 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Number of Incontinence Episodes Per 24 Hours at Week 12.</title>
          <description>Number of incontinence episodes was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
Incontinence is the complaint of any involuntary leakage of urine.
Change: mean at Week 12 minus mean at Baseline.</description>
          <population>Full analysis set. Last observation carried forward</population>
          <units>Incontinence Episodes</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="314"/>
                <count group_id="O3" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.88" lower_limit="-1.22" upper_limit="-0.54"/>
                    <measurement group_id="O2" value="-1.27" lower_limit="-1.61" upper_limit="-0.93"/>
                    <measurement group_id="O3" value="-1.15" lower_limit="-1.50" upper_limit="-0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The significance level was 0.05 (2-sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance model with the treatment group, region as fixed effects and baseline values as a covariate was used.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.63</ci_lower_limit>
            <ci_upper_limit>-0.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The significance level was 0.05 (2-sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.030</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance model with the treatment group, region as fixed effects and baseline values as a covariate was used.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.52</ci_lower_limit>
            <ci_upper_limit>-0.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Number of Incontinence Episodes Per 24 Hours at Weeks 2, 4, 8, and 12.</title>
        <description>Number of incontinence episodes was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
Incontinence is the complaint of any involuntary leakage of urine.
Change: mean at each visit minus mean at Baseline.</description>
        <time_frame>Baseline to Weeks 2, 4, 8, and 12</time_frame>
        <population>Full analysis set. No imputation was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subjects were treated with placebo once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 4 mg</title>
            <description>Subjects were treated with Fesoterodine 4 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg</title>
            <description>Subjects were treated with Fesoterodine 8 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Number of Incontinence Episodes Per 24 Hours at Weeks 2, 4, 8, and 12.</title>
          <description>Number of incontinence episodes was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
Incontinence is the complaint of any involuntary leakage of urine.
Change: mean at each visit minus mean at Baseline.</description>
          <population>Full analysis set. No imputation was used for missing data.</population>
          <units>Incontinence Episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="314"/>
                <count group_id="O3" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=308, 314, 305)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.80" spread="1.573"/>
                    <measurement group_id="O2" value="-1.11" spread="1.725"/>
                    <measurement group_id="O3" value="-1.06" spread="1.887"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=301, 303, 296)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.22" spread="1.598"/>
                    <measurement group_id="O2" value="-1.61" spread="1.755"/>
                    <measurement group_id="O3" value="-1.50" spread="1.707"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=289, 289, 287)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.56" spread="1.727"/>
                    <measurement group_id="O2" value="-1.76" spread="1.795"/>
                    <measurement group_id="O3" value="-1.73" spread="1.760"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=284, 284, 281)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.59" spread="1.869"/>
                    <measurement group_id="O2" value="-1.97" spread="1.843"/>
                    <measurement group_id="O3" value="-1.86" spread="2.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Number of Night-Time Micturitions Per 24 Hours at Week 12.</title>
        <description>Number of Night-Time Micturitions was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
Change: mean at Week 12 minus mean at Baseline.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>Among the full analysis set, participants who had mean number of night-time micturitions per 24 hours of greater than 0 at baseline .
Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subjects were treated with placebo once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 4 mg</title>
            <description>Subjects were treated with Fesoterodine 4 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg</title>
            <description>Subjects were treated with Fesoterodine 8 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Number of Night-Time Micturitions Per 24 Hours at Week 12.</title>
          <description>Number of Night-Time Micturitions was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
Change: mean at Week 12 minus mean at Baseline.</description>
          <population>Among the full analysis set, participants who had mean number of night-time micturitions per 24 hours of greater than 0 at baseline .
Last observation carried forward.</population>
          <units>Night-Time Micturitions</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="243"/>
                <count group_id="O2" value="256"/>
                <count group_id="O3" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.18" lower_limit="-0.41" upper_limit="0.06"/>
                    <measurement group_id="O2" value="-0.21" lower_limit="-0.44" upper_limit="0.02"/>
                    <measurement group_id="O3" value="-0.29" lower_limit="-0.52" upper_limit="-0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The significance level was 0.05 (2-sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.624</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance model with the treatment group, region as fixed effects and baseline values as a covariate was used.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.18</ci_lower_limit>
            <ci_upper_limit>0.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The significance level was 0.05 (2-sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.129</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance model with the treatment group, region as fixed effects and baseline values as a covariate was used.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.26</ci_lower_limit>
            <ci_upper_limit>0.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Number of Night-Time Micturitions Per 24 Hours at Weeks 2, 4, 8, and 12.</title>
        <description>Number of Night-Time Micturitions was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
Change: mean at each visit minus mean at Baseline.</description>
        <time_frame>Baseline to Weeks 2, 4, 8, and 12</time_frame>
        <population>Participants who had mean number of night-time micturitions per 24 hours of greater than 0 at baseline within the full analysis set.
No imputation was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subjects were treated with placebo once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 4 mg</title>
            <description>Subjects were treated with Fesoterodine 4 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg</title>
            <description>Subjects were treated with Fesoterodine 8 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Number of Night-Time Micturitions Per 24 Hours at Weeks 2, 4, 8, and 12.</title>
          <description>Number of Night-Time Micturitions was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
Change: mean at each visit minus mean at Baseline.</description>
          <population>Participants who had mean number of night-time micturitions per 24 hours of greater than 0 at baseline within the full analysis set.
No imputation was used for missing data.</population>
          <units>Night-Time Micturitions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="243"/>
                <count group_id="O2" value="256"/>
                <count group_id="O3" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=242, 256, 256)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" spread="0.696"/>
                    <measurement group_id="O2" value="-0.24" spread="0.796"/>
                    <measurement group_id="O3" value="-0.34" spread="0.809"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=236, 246, 248)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" spread="0.835"/>
                    <measurement group_id="O2" value="-0.30" spread="0.830"/>
                    <measurement group_id="O3" value="-0.46" spread="0.780"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=224, 232, 241)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="0.820"/>
                    <measurement group_id="O2" value="-0.45" spread="0.815"/>
                    <measurement group_id="O3" value="-0.58" spread="0.903"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=220, 229, 236)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.44" spread="0.945"/>
                    <measurement group_id="O2" value="-0.48" spread="0.882"/>
                    <measurement group_id="O3" value="-0.63" spread="0.945"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Voided Volume Per Micturition at Week 12.</title>
        <description>Voided volume per micturition was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
Voided volume was recorded during any 1 day of 3-day diary period through the first micturition of the next day.
Change: mean at Week 12 minus mean at Baseline.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>Full analysis set. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subjects were treated with placebo once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 4 mg</title>
            <description>Subjects were treated with Fesoterodine 4 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg</title>
            <description>Subjects were treated with Fesoterodine 8 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Voided Volume Per Micturition at Week 12.</title>
          <description>Voided volume per micturition was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
Voided volume was recorded during any 1 day of 3-day diary period through the first micturition of the next day.
Change: mean at Week 12 minus mean at Baseline.</description>
          <population>Full analysis set. Last observation carried forward.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="314"/>
                <count group_id="O3" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.07" spread="46.207"/>
                    <measurement group_id="O2" value="22.80" spread="47.590"/>
                    <measurement group_id="O3" value="32.77" spread="52.893"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Voided Volume Per Micturition at Weeks 2, 4, 8, and 12.</title>
        <description>Voided volume per micturition was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
Change: mean at each visit minus mean at Baseline.</description>
        <time_frame>Baseline to Weeks 2, 4, 8, and 12</time_frame>
        <population>Full analysis set. No imputation was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subjects were treated with placebo once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 4 mg</title>
            <description>Subjects were treated with Fesoterodine 4 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg</title>
            <description>Subjects were treated with Fesoterodine 8 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Voided Volume Per Micturition at Weeks 2, 4, 8, and 12.</title>
          <description>Voided volume per micturition was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
Change: mean at each visit minus mean at Baseline.</description>
          <population>Full analysis set. No imputation was used for missing data.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="314"/>
                <count group_id="O3" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=308, 314, 304)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.06" spread="37.875"/>
                    <measurement group_id="O2" value="13.63" spread="35.350"/>
                    <measurement group_id="O3" value="21.52" spread="42.946"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=301, 303, 296)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.23" spread="43.639"/>
                    <measurement group_id="O2" value="21.62" spread="44.623"/>
                    <measurement group_id="O3" value="27.41" spread="45.803"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=289, 289, 287)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.75" spread="45.628"/>
                    <measurement group_id="O2" value="22.05" spread="44.949"/>
                    <measurement group_id="O3" value="30.94" spread="51.258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=284, 284, 281)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.28" spread="46.317"/>
                    <measurement group_id="O2" value="24.52" spread="48.620"/>
                    <measurement group_id="O3" value="33.40" spread="53.379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Each Domain Scores of King's Health Questionnaire (KHQ).</title>
        <description>King's Health Questionnaire(KHQ) is used to assess the impact of bladder problems on quality of life. The each domain score was calculated valued and ranged from 0 to 100, where 0=best outcome/response and 100=worst outcome/response.
Change: mean at Week 12 minus mean at Baseline.</description>
        <time_frame>Baseline to Week12</time_frame>
        <population>Full analysis set. No imputation was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subjects were treated with placebo once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 4 mg</title>
            <description>Subjects were treated with Fesoterodine 4 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg</title>
            <description>Subjects were treated with Fesoterodine 8 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Each Domain Scores of King's Health Questionnaire (KHQ).</title>
          <description>King's Health Questionnaire(KHQ) is used to assess the impact of bladder problems on quality of life. The each domain score was calculated valued and ranged from 0 to 100, where 0=best outcome/response and 100=worst outcome/response.
Change: mean at Week 12 minus mean at Baseline.</description>
          <population>Full analysis set. No imputation was used for missing data.</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="285"/>
                <count group_id="O2" value="283"/>
                <count group_id="O3" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>General Health Perceptions (n=285, 283, 283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.02" spread="22.573"/>
                    <measurement group_id="O2" value="-9.36" spread="25.190"/>
                    <measurement group_id="O3" value="-6.10" spread="25.272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Impact on Life (n=285, 283, 283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.46" spread="28.018"/>
                    <measurement group_id="O2" value="-27.33" spread="29.960"/>
                    <measurement group_id="O3" value="-25.09" spread="32.172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Limitations (n=285, 283, 283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.47" spread="27.730"/>
                    <measurement group_id="O2" value="-27.92" spread="26.373"/>
                    <measurement group_id="O3" value="-25.97" spread="28.590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Limitations (n=285, 283, 283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.65" spread="28.250"/>
                    <measurement group_id="O2" value="-23.50" spread="28.807"/>
                    <measurement group_id="O3" value="-25.97" spread="28.278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Limitations (n=285, 283, 283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.44" spread="25.541"/>
                    <measurement group_id="O2" value="-17.92" spread="24.029"/>
                    <measurement group_id="O3" value="-18.53" spread="25.765"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Personal Relationships (n=214, 210, 202)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.33" spread="21.773"/>
                    <measurement group_id="O2" value="-16.11" spread="25.798"/>
                    <measurement group_id="O3" value="-9.98" spread="24.335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotions (n=285, 283, 283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.01" spread="26.365"/>
                    <measurement group_id="O2" value="-24.70" spread="27.192"/>
                    <measurement group_id="O3" value="-24.89" spread="27.310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep/Energy (n=285, 283, 283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.51" spread="24.967"/>
                    <measurement group_id="O2" value="-19.08" spread="23.800"/>
                    <measurement group_id="O3" value="-18.02" spread="25.287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Incontinence Severity Measures (n=285, 283, 283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.75" spread="20.763"/>
                    <measurement group_id="O2" value="-17.67" spread="21.038"/>
                    <measurement group_id="O3" value="-18.59" spread="21.814"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Each Domain Scores of Overactive Bladder Questionnaire (OAB-q) at Week 12.</title>
        <description>The overactive bladder questionnaire (OAB-q) is used to assess the extent of participants who had been bothered by selected bladder symptoms and to assess the effect on their health-related quality of life (HRQL).
The each domain score ranges from 0 to 100 is a calculated value, where 0=minimal symptom severity and 100=greatest symptom severity for Symptom Bother Score, and where 0=worst HRQL outcome/response and 100=best HRQL outcome/response for HRQL domains including total score of HROL domain.
Change: mean at Week 12 minus mean at Baseline.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>Full analysis set. Half scale rule (domain scores were calculated if a respondent had answered at least half of the items in a multi-item scale. Missing items were then replaced by the mean of non-missing items in that scale, for that participant.)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subjects were treated with placebo once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 4 mg</title>
            <description>Subjects were treated with Fesoterodine 4 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg</title>
            <description>Subjects were treated with Fesoterodine 8 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Each Domain Scores of Overactive Bladder Questionnaire (OAB-q) at Week 12.</title>
          <description>The overactive bladder questionnaire (OAB-q) is used to assess the extent of participants who had been bothered by selected bladder symptoms and to assess the effect on their health-related quality of life (HRQL).
The each domain score ranges from 0 to 100 is a calculated value, where 0=minimal symptom severity and 100=greatest symptom severity for Symptom Bother Score, and where 0=worst HRQL outcome/response and 100=best HRQL outcome/response for HRQL domains including total score of HROL domain.
Change: mean at Week 12 minus mean at Baseline.</description>
          <population>Full analysis set. Half scale rule (domain scores were calculated if a respondent had answered at least half of the items in a multi-item scale. Missing items were then replaced by the mean of non-missing items in that scale, for that participant.)</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="285"/>
                <count group_id="O2" value="283"/>
                <count group_id="O3" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Symptom Bother Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.25" spread="23.618"/>
                    <measurement group_id="O2" value="-26.61" spread="22.592"/>
                    <measurement group_id="O3" value="-26.35" spread="23.849"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Score of HRQL domain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.88" spread="18.868"/>
                    <measurement group_id="O2" value="17.84" spread="17.880"/>
                    <measurement group_id="O3" value="17.29" spread="19.670"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Coping Score of HRQL domain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.54" spread="23.633"/>
                    <measurement group_id="O2" value="21.01" spread="22.109"/>
                    <measurement group_id="O3" value="21.48" spread="25.336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Concern Score of HRQL domain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.25" spread="21.182"/>
                    <measurement group_id="O2" value="20.05" spread="20.526"/>
                    <measurement group_id="O3" value="19.10" spread="21.868"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep Score of HRQL domain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.03" spread="22.215"/>
                    <measurement group_id="O2" value="16.16" spread="21.886"/>
                    <measurement group_id="O3" value="15.35" spread="24.654"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Score of HRQL domain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.37" spread="17.211"/>
                    <measurement group_id="O2" value="11.35" spread="16.504"/>
                    <measurement group_id="O3" value="9.98" spread="16.706"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline for Patient Perception of Bladder Condition (PPBC) at Week 12.</title>
        <description>Patient Perception of Bladder Condition (PPBC) score is rated on a 6-point scale as follows:
No problems at all
Some very minor problems
Some minor problems
Some moderate problems
Severe problems
Many severe problems
Change: mean at Week 12 minus mean at Baseline.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>Full analysis set. No imputation was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subjects were treated with placebo once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 4 mg</title>
            <description>Subjects were treated with Fesoterodine 4 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg</title>
            <description>Subjects were treated with Fesoterodine 8 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline for Patient Perception of Bladder Condition (PPBC) at Week 12.</title>
          <description>Patient Perception of Bladder Condition (PPBC) score is rated on a 6-point scale as follows:
No problems at all
Some very minor problems
Some minor problems
Some moderate problems
Severe problems
Many severe problems
Change: mean at Week 12 minus mean at Baseline.</description>
          <population>Full analysis set. No imputation was used for missing data.</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="285"/>
                <count group_id="O2" value="283"/>
                <count group_id="O3" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.57" spread="1.236"/>
                    <measurement group_id="O2" value="-1.83" spread="1.157"/>
                    <measurement group_id="O3" value="-1.76" spread="1.182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Patients With Severe Problems, Score 5 or Many Severe Problems, Score 6 in Patient Perception of Bladder Condition (PPBC) at Week 12.</title>
        <description>Patient Perception of Bladder Condition (PPBC) score is rated on a 6-point scale as follows:
No problems at all
Some very minor problems
Some minor problems
Some moderate problems
Severe problems
Many severe problems</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>Full analysis set. No imputation was used for missing data</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subjects were treated with placebo once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 4 mg</title>
            <description>Subjects were treated with Fesoterodine 4 mg/day for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Fesoterodine 8 mg</title>
            <description>Subjects were treated with Fesoterodine 8 mg/day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Patients With Severe Problems, Score 5 or Many Severe Problems, Score 6 in Patient Perception of Bladder Condition (PPBC) at Week 12.</title>
          <description>Patient Perception of Bladder Condition (PPBC) score is rated on a 6-point scale as follows:
No problems at all
Some very minor problems
Some minor problems
Some moderate problems
Severe problems
Many severe problems</description>
          <population>Full analysis set. No imputation was used for missing data</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="285"/>
                <count group_id="O2" value="283"/>
                <count group_id="O3" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="97"/>
                    <measurement group_id="O3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Subjects were treated with placebo once daily for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Fesoterodine 4 mg</title>
          <description>Subjects were treated with Fesoterodine 4 mg/day for 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Fesoterodine 8 mg</title>
          <description>Subjects were treated with Fesoterodine 8 mg/day for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="320"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="320"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="320"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="320"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="320"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="138" subjects_at_risk="320"/>
                <counts group_id="E3" subjects_affected="185" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="320"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="320"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="320"/>
                <counts group_id="E3" subjects_affected="158" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="320"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="320"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="320"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="320"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="320"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Residual urine</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="320"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of &lt; 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), &lt; 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.govCallCenter@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

